Site Editor

Thomas Flaig, MD


Andrea Necchi, MD, on KEYNOTE-057: Pembrolizumab Monotherapy May Benefit Some Patients With Bladder Cancer

Posted: Friday, February 24, 2023

Andrea Necchi, MD, of Italy’s Vita-Salute San Raffaele University and the IRCCS San Raffaele Hospital and Scientific Institute, discusses the possible ramifications of recent findings from the KEYNOTE-057 trial on a novel systemic therapy for papillary high-risk non–muscle-invasive bladder cancer. The data suggest that patients whose disease does not respond to bacillus Calmette-Guérin or who declined or were ineligible for a radical cystectomy may benefit from pembrolizumab monotherapy, which showed antitumor activity after about 45 months of follow-up.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.